CD36 as a target to prevent cardiac lipotoxicity and insulin resistance  by Glatz, Jan F.C. et al.
Prostaglandins, Leukotrienes and Essential Fatty Acids 88 (2013) 71–77Contents lists available at SciVerse ScienceDirectProstaglandins, Leukotrienes and Essential
Fatty Acids0952-32
http://d
n Corr
E-m
1 Pr
Lausann
2 Pr
Humanjournal homepage: www.elsevier.com/locate/plefaCD36 as a target to prevent cardiac lipotoxicity and insulin resistanceJan F.C. Glatz n, Yeliz Angin, Laura K.M. Steinbusch 1, Robert W. Schwenk 2, Joost J.F.P. Luiken
Department of Molecular Genetics, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlandsa r t i c l e i n f o
Keywords:
Lipotoxicity
Insulin resistance
CD36
Vesicle-associated membrane protein78 & 2012 Elsevier Ltd.
x.doi.org/10.1016/j.plefa.2012.04.009
esponding author. Tel.: þ31 433881998; fax:
ail address: glatz@maastrichtuniversity.nl (J.F
esent address: Center for Integrative Genom
e, Switzerland.
esent address: Department of Experimental Dia
Nutrition Potsdam-Rehbruecke, Germany.
Open access under the Ela b s t r a c t
The fatty acid transporter and scavenger receptor CD36 is increasingly being implicated in the
pathogenesis of insulin resistance and its progression towards type 2 diabetes and associated
cardiovascular complications. The redistribution of CD36 from intracellular stores to the plasma
membrane is one of the earliest changes occurring in the heart during diet induced obesity and insulin
resistance. This elicits an increased rate of fatty acid uptake and enhanced incorporation into
triacylglycerol stores and lipid intermediates to subsequently interfere with insulin-induced GLUT4
recruitment (i.e., insulin resistance). In the present paper we discuss the potential of CD36 to serve as a
target to rectify abnormal myocardial fatty acid uptake rates in cardiac lipotoxic diseases. Two
approaches are described: (i) immunochemical inhibition of CD36 present at the sarcolemma and
(ii) interference with the subcellular recycling of CD36. Using in vitro model systems of high-fat diet
induced insulin resistance, the results indicate the feasibility of using CD36 as a target for adaptation of
cardiac metabolic substrate utilization. In conclusion, CD36 deserves further attention as a promising
therapeutic target to redirect fatty acid ﬂuxes in the body.
& 2012 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
The healthy heart is characterized by a high rate of (long-
chain) fatty acid metabolism. Besides glucose, fatty acids com-
prise a major substrate for metabolic energy production continu-
ously needed to sustain myocardial contraction [1]. Because
under normal conditions the heart stores only small amounts of
fat, there is a constant need to extract these fatty acids from
plasma. As a result, in the heart there is a ﬁne-tuning of high rates
of myocellular fatty acid uptake and of mitochondrial b-oxidation.
When this dynamic interplay between fatty acid uptake and
metabolism is disturbed, this will result in cardiac pathology.
For instance, when the rate of fatty acid delivery to the heart is
increased such as during high-fat feeding, the rate of fatty acid
oxidation will increase and fatty acids become the predominant
substrate, but eventually the uptake will still exceed the rate of
oxidation so that fatty acids will be stored intracellularly into
triacylglycerols. Likewise, when fatty acid oxidation is impaired
such as in the case of carnitine deﬁciency or inborn errors of fatty
acid b-oxidation [2], only part of the incoming fatty acids can
enter the oxidation pathway and a major portion is esteriﬁed intoþ31 433884574.
.C. Glatz).
ics, Universite´ de Lausanne,
betology, German Institute of
sevier OA license.triacylglycerols. When such lipid storage becomes excessive it is
associated with impaired cardiac functioning [3]. This latter
condition is referred to as cardiac lipotoxicity [4].
In recent years our understanding of the regulation of cellular
fatty acid uptake has markedly increased. Particularly, fatty acid
uptake was found to occur by a mechanism that resembles that of
cellular glucose uptake reviewed in [5]. In response to an external
trigger such as insulin (on adipocytes, heart and skeletal muscle)
or to (an increase in) muscular contraction (of heart and skeletal
muscle), speciﬁc fatty acid transporters translocate from intracel-
lular stores to the plasma membrane to facilitate fatty acid
uptake, just as these same stimuli recruit glucose transporters
to increase cellular glucose uptake. In the heart, the main fatty
acid transporter that functions by this mechanism is the mem-
brane protein CD36. Fatty acid transporters, especially CD36, have
been implicated in the pathogenesis of diseases involving altera-
tions in cellular lipid metabolism, including cardiac lipotoxicity.
Consequently, fatty acid transporters may serve as molecular
target to rectify abnormal tissue fatty acid handling. In the
present paper we will explore the possibility of selective targeting
of CD36 as therapeutic intervention.2. Pivotal role of CD36 in myocardial fatty acid uptake
CD36 is a 472-amino acid, heavily glycosylated transmem-
brane protein (88 kDa) that is well established to facilitate the
uptake of (long-chain) fatty acids into adipocytes, heart, and
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Fig. 1. Two-photon imaging of sarcolemmal CD36 in control cardiomyocytes (left) and after insulin treatment (right). Cardiomyocytes were isolated from adult male Lewis
rats and short-term (15 min) treated with or without 100 nM insulin. Cells then were incubated with mouse anti-mouse CD36 mAb (clone 63), which is known to cross-
react with rat CD36, and FITC labeled rabbit–anti–mouse IgA secondary antibodies. Subsequent imaging of the cardiomyocytes was done using the Leica SP5 imaging
platform in two-photon mode (Leica Microsystems, Wetzlar, Germany) with the emission ﬁlters optimized for FITC detection. The image shown is representative for three
observations.
Heart echo-cardiography
83%*
2.3*
96%
1.9*
FS: 100%
PM/IM ratio: 1.0
8 wks4 wksStart
CD36 immunolocalisation
Fig. 2. High-fat diet induces CD36 redistribution to the sarcolemma and left
ventricular dysfunction in rats. Adult male Wistar rats received a high-fat diet
(50 en% fat) for 8 weeks. Top panel: CD36 localization was studied in sections from
parafﬁn-embedded left ventricular tissue obtained from animals sacriﬁced at the
start and after 4 and 8 weeks dietary intervention. Immunohistochemical staining
of CD36 was performed with the anti-CD36 monoclonal antibody MO25 and
visualized with peroxidase reaction. From these images the ratio of CD36 presence
at the plasmamembrane (PM) to that at intracellular membranes (IM) was
calculated. Arrows indicate intercalated disks. Scale bar indicates 25 mM. Note
that Western blot analysis revealed that total CD36 protein content did not change
(data not shown). Lower panel: Echocardiography was performed and fractional
shortening (FS) calculated at the start and after 4 and 8 weeks on high-fat diet (the
value at the start was set at 100%). Representative images are shown. Data
obtained from [19].
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translocase (FAT) [5–7]. CD36 is also known from its function in
platelets (thrombospondin binding), in macrophages (scavenger
receptor for oxidized LDL), and as gustatory lipid sensor reviewed
in [8]. Studies in CD36 null mice have revealed that CD36
contributes for approximately 70% to fatty acid uptake into
contracting cardiac myocytes [9]. The importance of CD36 also
follows from the observation that mutations in the CD36 gene
may markedly affect myocardial fatty acid uptake. For instance,
Tanaka et al. [10] reported a patient with two mutations in the
CD36 gene that caused a virtual absence of fatty acid uptake as
monitored using 123I-BMIPP and SPECT imaging.
A role for CD36 in the regulation of cardiac fatty acid uptake
was disclosed when it was found that about 50% of the cellular
amount of CD36 is stored in intracellular compartments from
where it can be recruited to the sarcolemma to increase the rate
of fatty acid uptake [11]. CD36 translocation to the sarcolemma is
a rapid and reversible process (Fig. 1) [12], and is triggered by
insulin, muscle contraction, and pharmacological agents such as
caffeine [13], AICAR, phenylephrine, and okadaic acid (Luiken,
JJFP, unpublished observation). At the extracellular site CD36
shows protein–protein interaction with plasmamembrane fatty
acid-binding protein (FABPpm), a peripheral membrane protein
with a ubiquitous tissue occurrence [14], and at the intracellular
site with cytoplasmic FABP that will bind the incoming fatty acids
and facilitate their transport to sites of utilization [5,15,16].
Finally, the heart also expresses three members of the family of
fatty acid-transport proteins (FATPs), i.e., FATP1, FATP4, and
FATP6, but these proteins merely function in the uptake of very
long-chain fatty acids (chain length 422) which by action of the
synthetase activity of the FATPs are converted directly into very
long-chain acyl-CoA esters [17]. Moreover, the FATPs have been
shown not to be regulated by reversible translocation, at least not
in the heart [18].3. CD36 in cardiac metabolic disease
Various studies have shown the involvement of CD36 in the
increased cardiac fatty acid utilization seen in obesity and type
2 diabetes. When rats were subjected to a high-fat diet (50 en%)
during 8 weeks, both fatty acid uptake and fatty acid esteriﬁcation
into triacylglycerols measured in isolated cardiomyocytes were
increased 1.4–fold when compared to rats fed a low-fat diet
(16 en% fat). Total tissue CD36 content was unchanged; however
CD36 was relocated to the sarcolemma (2-fold increase; Fig. 2).
Cardiac function monitored in vivo by echocardiography revealed
a decreased fractional shortening and a lower ejection fraction,indicating cardiac contractile dysfunction (Fig. 2). Interestingly,
the increase in sarcolemmal CD36 was seen already after 4 weeks
on high-fat diet, when contractile function had not yet changed.
Therefore, these combined observations led to the conclusion that
exposure to a high-fat diet ﬁrst induces a relocation of CD36 to the
sarcolemma and an associated increase in cardiac fatty acid uptake,
and subsequently leads to cardiac contractile dysfunction [19].
Similar observations have been made in human studies which,
understandably, have focused on the more accessible skeletal
muscle. Bonen et al. [20] showed that in human obesity and type
2 diabetes the increased rate of fatty acid transport into skeletal
muscle was associated with an increase in sarcolemmal CD36.
Furthermore, in obesity the rate of fatty acid esteriﬁcation was
increased while concomitantly the rate of fatty acid oxidation was
not altered, suggesting that the increased rate of CD36-mediated
fatty acid transport may contribute to the increased rate of
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obese, and type 2 diabetic individuals, muscle triacylglycerol
content was positively correlated with the sarcolemmal CD36
content [20]. Subsequent studies in obese patients by Aguer et al.
[21] also revealed that intramyocellular lipid accumulation is
related to sarcolemmal CD36 relocation.
The above observations suggest that CD36 can be regarded as a
key factor in the etiology of obesity-induced insulin resistance
and type 2 diabetes. Our current understanding is that early in the
development of insulin resistance alterations occur in the signal-
ing cascades and/or trafﬁcking proteins speciﬁcally dedicated to
subcellular CD36 recycling, which would result in a selective and
permanent relocation of CD36 to the sarcolemma. Importantly, at
this stage there would be no concurrent change in the subcellular
distribution of the glucose transporter GLUT4. The increased
sarcolemmal CD36 abundance, together with an increased plasma
fatty acid concentration, would elicit an increased rate of fatty
acid uptake and esteriﬁcation into triacylglycerols, and increased
concentrations of fatty acid metabolites such as diacylglycerols
and ceramides, as has been shown [22]. The latter compounds
will then interfere with insulin-induced GLUT4 translocation to
the sarcolemma so that GLUT4 is retained intracellularly and the
rate of glucose uptake is lowered, i.e., insulin resistance (Fig. 3).
This scenario would provide a mechanism for the observation that
during the development of obesity-induced insulin resistance and
its progression towards type 2 diabetes and diabetic cardiomyo-
pathy, changes in fatty acid metabolism precede a change in
glucose uptake.4. CD36 as target of metabolic modulation
Based on the key role of CD36 in the early metabolic changes
occurring in cardiac myocytes during the development of insulin
resistance and type 2 diabetes, it is hypothesized that CD36 may
serve as a therapeutic target for the prevention and/or treatment of
insulin resistance and diabetes related cardiac contractile dysfunc-
tion. Speciﬁcally, the intervention would be aimed at limiting
CD36-mediated cardiac fatty acid uptake, which in turn would
normalize the rate of intracellular fatty acid esteriﬁcation into
triacylglycerols, thereby lowering intramyocardial lipid storage
and excess production of fatty acid metabolites. The latter would
relieve their inhibitory action on insulin-induced GLUT4 transloca-
tion and normalize cardiac glucose uptake and utilization.Glucose 
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Fig. 3. Juxtaposition of the substrate transporters CD36 and GLUT4 in insulin-resistant
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chain fatty acid; DAG, diacylglyceroles; cer, ceramides; IR, insulin resistance.A number of experimental studies with transgenic mouse models
have indicated the feasibility of this concept. Yang et al. [23] studied
mice with a cardiac-restricted overexpression of peroxisome prolif-
erator-activated receptor a (PPARa) which results in a twofold
increased myocardial lipid accumulation and left ventricular systolic
dysfunction. When these mice were cross-bred with CD36 null
animals, both lipid accumulation and systolic function were normal-
ized, suggesting that the absence of CD36 rescues cardiac dysfunction
in a genetic model of cardiac lipotoxicity [23]. A physiologically more
relevant study was performed by Steinbusch et al. [24]. Mice
subjected to a Western-type (high-fat and high-sucrose) diet for 10
weeks showed an 1.8-fold increased cardiac lipid content but normal
cardiac contractile function (Fig. 4, left panel). When these mice
subsequently underwent surgery for transverse aortic constriction
(TAC), which elicits high blood pressure, they developed cardiac
hypertrophy and dysfunction, indicating that a mechanical stress
(TAC) on top of a metabolic stress (increased lipid metabolism)
induces cardiac dysfunction and remodeling. When these interven-
tions were made on CD36 null mice, cardiac lipid accumulation was
prevented and TAC-induced cardiac functional and structural changes
remained absent (Fig. 4, right panel). Together, these data indicate
that CD36 ablation prevents the metabolic stress resulting from a
Western-type diet, so that the heart can better cope with the
mechanophysical stress that results from high blood pressure [24].
In a broader context, this study also provides evidence that metabolic
conditions are a critical factor for the compromised heart and thus
warrant further attention.5. Approaches to target CD36
In principle, targeting of CD36-mediated fatty acid uptake
could involve either (i) the functioning of CD36 present at the
sarcolemma or (ii) the subcellular recycling of CD36 so as to limit
its presence at the sarcolemma. Both approaches will be
discussed.
5.1. Inhibition of sarcolemmal CD36
Sulfo-N-succinimidyl esters of long-chain fatty acids are well-
known inhibitors of the fatty acid transport function of CD36
since these compounds were used for the disclosure of this
function for CD36 [6]. For instance, sulfo-N-succinimidyl oleate
(SSO) effectively and completely blocks CD36-mediated fatty acidAlbumin 
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ajor substrate for energy production (step 3). Subsequently, fatty acid metabolites
UT4 from endosomes to the sarcolemma is impaired (step 4), resulting in lowered
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Fig. 4. Absence of CD36 protects against Western-type diet-induced cardiac lipid accumulation (left) and cardiac dysfunction following pressure overload (right) in mice.
Wild-type (WT) and CD36 null (CD36) mice were fed either standard rodent diet (chow) or a Western-type (high fat and high sucrose) diet (WTD) for 10 weeks.
Thereafter, mice either were sham operated or underwent transverse aortic constriction (TAC) to induce pressure overload. Diet exposure was continued. Six weeks after
surgery, cardiac function (left ventricle fractional shortening) was determined by echocardiography, whereafter the mice were sacriﬁced for a.o. biochemical
determination of cardiac lipid content. Data obtained from [24]. Statistical analysis was done by 2-way ANOVA (with Po0.05 considered signiﬁcant): * vs. WT on
chow diet, 4vs. CD36 / on chow diet, $ vs. WT/TAC on chow diet.
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succinimidyl esters cannot be used in long-term experiments or
in vivo because of their chemical instability [26]. Other ligands
that have been described to inﬂuence CD36 function include the
hexapeptides hexarelin and EP80317. Hexarelin, a synthetic
growth hormone releasing (hexa)peptide (GHRP), was shown to
exert its cardiovascular activity (increase in coronary perfusion
pressure in isolated perfused hearts) by binding to CD36 in a dose
dependent manner [27]. The closely related synthetic hexapep-
tide EP80317 has been described to reduce atherosclerotic lesions
in ApoE null mice in a CD36 dependent manner [28]. However,
both hexarelin and EP80317 (up to 100 mM) do not affect the rate
of fatty acid uptake by isolated rat cardiomyocytes (Angin Y,
Steinbusch LKM, unpublished observations). As a result, at pre-
sent no chemical compounds are known that are suitable for
long-term inhibition of the role of CD36 in facilitating cellular
fatty acid uptake.
Speciﬁc antibodies raised against CD36 are commonly used for
immunolocalization studies and Western blotting analyses.
Selected antibodies also block CD36 function [29]. However,
interestingly, antibodies selected for their inhibition of throm-
bospondin binding did not affect the fatty acid transport function
of CD36 (Luiken JJFP and Bonen A, unpublished observations). In a
recent study we used monoclonal antibody clone 63 (also known
as clone CRF D2717) raised against mouse CD36 to study whether
antibody inhibition of CD36 prevents lipid accumulation and
contractile function in rat cardiomyocyte cultures.
Isolated rat cardiomyocytes were cultured for 48 h in a
medium containing a relatively high concentration (200 mM) of
palmitate, a condition that is know to elicit insulin resistance [30]
and reduce contractile function [31]. Indeed, after 48 h of culture
in this high-palmitate containing medium, the rate of basal fatty
acid uptake was increased 1.6-fold when compared to cells
cultured under control conditions (no added palmitate) and was
accompanied by a 4.4-fold increased cellular triacylglycerol con-
tent (Fig. 5). Concomitantly, the sarcolemmal presence of CD36
was markedly increased (data not shown). While insulin was able
to stimulate fatty acid uptake in control cells (by 1.5-fold),cardiomyocytes cultured in high-palmitate medium did not
respond to insulin (Fig. 5), thus reﬂecting the induction of insulin
resistance. Likewise, glucose uptake was affected in a similar
manner (data not shown). The same set of experiments were also
performed in the presence of anti-CD36 antibodies added to the
culture medium at the start of the 48 h incubation. The addition
of these antibodies prevented the increase in basal fatty acid
uptake and loss of its insulin-responsiveness seen in the presence
of high palmitate alone (Fig. 5). Importantly, the antibodies
completely prevented the high-palmitate induced increase in
triacylglycerol content. Taken together, these data demonstrate
that immunochemical inhibition of CD36 prevents elevated fatty
acid uptake, lipid accumulation, and possibly contractile dysfunc-
tion in cardiomyocytes cultured in a lipotoxic medium.
5.2. Modulation of subcellular CD36 recycling
The presence of CD36 at the sarcolemma is the net result of the
rate of CD36 translocation from endosomes to the sarcolemma
(exocytosis) and the rate of CD36 internalization towards its
intracellular storage compartment (endocytosis). Like with other
membrane transporters such as the glucose transporter GLUT4
and lipoprotein receptors, both of these processes are under the
control of a large number of proteins that together form the so-
called trafﬁcking machinery [32]. One of the families of trafﬁcking
proteins involved is that of soluble N-ethylmaleimide-sensitive
factor attachment protein receptors (SNAREs). These proteins are
present at the transport vesicle (v-SNAREs) and the target
membrane (t-SNAREs), and are mediators of membrane fusion
[33]. This process is highly selective as a v-SNARE interacts with
only a speciﬁc subset of t-SNAREs to form a SNARE complex that
initiates fusion. For instance, at the plasma membrane the
v-SNARE vesicle-associated membrane protein-2 (VAMP2) inter-
acts with the t-SNAREs syntaxin4 and SNAP23 to initiate fusion of
GLUT4-containing vesicles with the plasma membrane upon
insulin stimulation [34].
We examined the involvement of members of the VAMP
protein family in the subcellular trafﬁcking of GLUT4 and CD36
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to be required for both GLUT4 and CD36 translocation, either
speciﬁcally in insulin-induced translocation (VAMP2, VAMP5) or in
contraction-induced translocation (VAMP3). In addition, VAMP7
was found to be speciﬁcally involved in GLUT4 trafﬁc (mediating
basal GLUT4 retention) and VAMP4 speciﬁcally in CD36 trafﬁc
(both insulin- and contraction-induced translocation) [35]. Fig. 6
(upper panel) shows the plasmalemmal abundance of CD36 afterknock-down of the genes encoding for the various VAMP isoforms,
both under basal conditions (white bars) and after stimulation by
insulin (gray bars) or contraction (black bars). The changes in CD36
presence at the sarcolemma correlate with concomitant changes in
the rate of fatty acid uptake by the transfected cells (Fig. 6, lower
panel). These observations indicate the possibility to use VAMPs to
discriminate between GLUT4 and CD36 translocation, and thus
separately modulate cardiac glucose and fatty acid uptake.
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manipulating the presence of selective VAMPs in cardiomyocytes
and then monitor the vulnerability of the cells for lipotoxic condi-
tions. For instance, we hypothesize that overexpression of VAMP3
might prevent the development of insulin resistance in these cells
because this VAMP isoform is speciﬁcally required for contraction-
induced transporter translocation, and VAMP3 overexpression may
thus mimick the effects observed after acute exercise.6. Concluding remarks
Abnormal rates of fatty acid uptake and/or utilization by the
heart are seen under a number of conditions, and are often
associated with cardiac disease. In this paper we focused on a
mismatch between fatty acid uptake and oxidation which leads to
an excessive intracellular storage of fatty acids into di- and
triacylglycerols and subsequent cardiac dysfunction, a condition
referred to as cardiac lipotoxicity. Myocardial fatty acid uptake is
largely regulated by the membrane fatty acid transporter CD36,
especially through its continuous recycling from intracellular
stores to the sarcolemma triggered by a.o. insulin and myocyte
contractions. In view of this pivotal role of CD36 in governing
myocardial fatty acid uptake, it was hypothesized that manipulat-
ing CD36 will affect the rate of fatty acid uptake and thus may
serve as a useful therapeutic intervention to restore abnormalities
in the matching of cellular fatty acid uptake to oxidation. Both
inhibition of sarcolemmal CD36 and manipulation of the subcel-
lular trafﬁcking of CD36 were shown in in vitro model systems to
be effective approaches to normalize aberrant fatty acid handling
and features of cardiolipotoxicity seen under lipotoxic conditions.
As a result, selective targeting of CD36 holds promise as therapeu-
tic intervention. Future studies with more complex model systems
(e.g., intact perfused heart) and in vivo experimental animals
should be performed to examine whether this proof-of-concept
may be extrapolated to routine medical treatment.
Two approaches were used to affect the role of CD36 in myocar-
dial fatty acid uptake in the in vitro model systems, i.e., immuno-
chemical inhibition and overexpression of one of the trafﬁcking
proteins speciﬁcally involved in CD36 recycling (when compared to
that of GLUT4). Inhibition of CD36 in vivo is expected to be more
feasible with speciﬁc ligands of small molecular size (o1 kD) so that
these can easily pass through the endothelial clefts and reach the
cardiac myocytes. Sulfo-N-succinimidyl-esters of long-chain fatty
acids were found not useful because of their chemical instability
when in aqueous solution [26]. Compounds that would speciﬁcally
target selected members of the trafﬁcking proteins involved in CD36
recycling to our knowledge have not been described. Alternatively,
selected activation of signaling proteins upstream of the trafﬁcking
proteins would also be a theoretical option.
It should be kept in mind that our current understanding of
the regulation of CD36 presence and function at the sarcolemma
in relation to myocardial fatty acid uptake is only limited. For
instance, CD36 is hypothesized to function in speciﬁc regions of
the sarcolemma, e.g. microdomains like lipid rafts, and caveolae,
and does so in interaction with speciﬁc partner proteins such as
FABPpm and perhaps other (membrane-associated or other)
proteins. For instance, for 3T3-L1 adipocytes it was shown that
plasma membrane lipid rafts regulate the surface availability of
CD36 and thereby control fatty acid uptake [36]. Similarly, the
role of the many glycosylation sites of CD36 remains under-
explored, although very recently evidence was reported for the
importance of O-linked-b-N-acetylglucosamine for the mem-
brane recruitment of CD36 and its role in fatty acid uptake [37].
Finally, CD36 is welldocumented to have two extracellular phos-
phorylation sites (at Thr-92 and Ser-237) but their signiﬁcance isstill unclear [reviewed in 5]. As a result, it is feasible that the
functioning of CD36 as a sarcolemmal fatty acid transporter may
also be manipulated by other approaches than described here.
The in vitro model systems applied in the present work may be
used for screening purposes.Acknowledgments
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